Collegium Pharmaceutical Q1 2023 Earnings Report $33.35 -0.11 (-0.33%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Collegium Pharmaceutical EPS ResultsActual EPS$1.18Consensus EPS $1.20Beat/MissMissed by -$0.02One Year Ago EPSN/ACollegium Pharmaceutical Revenue ResultsActual Revenue$144.77 millionExpected Revenue$139.11 millionBeat/MissBeat by +$5.66 millionYoY Revenue GrowthN/ACollegium Pharmaceutical Announcement DetailsQuarterQ1 2023Date5/4/2023TimeN/AConference Call ResourcesSlide DeckPress ReleaseCOLL Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Collegium Pharmaceutical Earnings HeadlinesCollegium Pharmaceutical (NASDAQ:COLL) Upgraded at Needham & Company LLCJanuary 13, 2025 | americanbankingnews.comCollegium Pharmaceutical's (COLL) Buy Rating Reaffirmed at HC WainwrightJanuary 12, 2025 | americanbankingnews.comHenry Kissinger’s warning of Trump In this video, you’ll also get nine other Trump-connected investments… All of which we believe could have as much as 10-fold potential over the next four years…but only for those who get in now before Trump enters the Oval Office and unleashes America’s full economic might. January 18, 2025 | Porter & Company (Ad)Needham Upgrades Collegium Pharmaceutical (COLL)January 10, 2025 | msn.comCollegium Pharmaceutical’s Promising Growth and Undervalued Potential: A Buy Rating by Serge BelangerJanuary 10, 2025 | markets.businessinsider.comCollegium Pharmaceutical upgraded to Buy from Hold at NeedhamJanuary 10, 2025 | markets.businessinsider.comSee More Collegium Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Collegium Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Collegium Pharmaceutical and other key companies, straight to your email. Email Address About Collegium PharmaceuticalCollegium Pharmaceutical (NASDAQ:COLL), a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.View Collegium Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
